Literature DB >> 19640010

Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Maureen P M H Rutten-van Mölken1, Martine Hoogendoorn, Leida M Lamers.   

Abstract

BACKGROUND: There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases.
OBJECTIVE: This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a societal perspective.
METHODS: We developed 16 COPD health profiles. Each profile combined a description of the severity of COPD during the stable phase with a description of the exacerbation profile in terms of severity, frequency and duration. These profiles were valued by a representative sample of 239 Dutch adults using the visual analogue scale (VAS) and time trade-off (TTO) methods. Value functions were estimated using random effects regression analysis.
RESULTS: Both VAS and TTO values consistently decreased as severity of the COPD profiles increased. Estimated TTO values ranged from 0.97 for mild COPD without exacerbations to 0.43 for very severe COPD with one non-serious and one serious exacerbation per year. The estimated decrements in TTO values ranged from 0.010 for having one non-serious exacerbation to 0.088 for having one non-serious plus one serious exacerbation per year.
CONCLUSIONS: The value function may be an alternative way to model the joint impact of COPD severity and exacerbations on utility values in health economic modelling studies.

Entities:  

Mesh:

Year:  2009        PMID: 19640010     DOI: 10.2165/00019053-200927060-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  32 in total

1.  The measurement of utility in multiphase health states.

Authors:  J Richardson; J Hall; G Salkeld
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

2.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

Review 3.  Time preference for health in cost-effectiveness analysis.

Authors:  J Lipscomb
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

4.  The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty.

Authors:  M Johannesson
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

5.  Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Authors:  Jan B Oostenbrink; Maureen P M H Rutten-van Mölken; Brigitta U Monz; J Mark FitzGerald
Journal:  Value Health       Date:  2005 Jan-Feb       Impact factor: 5.725

Review 6.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Authors:  W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

8.  Health status impairment and costs associated with COPD exacerbation managed in hospital.

Authors:  J F O'Reilly; A E Williams; L Rice
Journal:  Int J Clin Pract       Date:  2007-07       Impact factor: 2.503

Review 9.  COPD exacerbations: the importance of a standard definition.

Authors:  R Pauwels; P Calverley; A S Buist; S Rennard; Y Fukuchi; E Stahl; C G Löfdahl
Journal:  Respir Med       Date:  2004-02       Impact factor: 3.415

Review 10.  COPD exacerbations: definitions and classifications.

Authors:  S Burge; J A Wedzicha
Journal:  Eur Respir J Suppl       Date:  2003-06
View more
  16 in total

1.  Utility estimation in chronic obstructive pulmonary disease: a preference for change?

Authors:  Jennifer Petrillo; Floortje van Nooten; Paul Jones; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  What should we know about the person behind a TTO?

Authors:  Floortje van Nooten; Jan Busschbach; Michel van Agthoven; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2018-12

3.  Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD.

Authors:  Kate M Johnson; Mohsen Sadatsafavi; Amin Adibi; Larry Lynd; Mark Harrison; Hamid Tavakoli; Don D Sin; Stirling Bryan
Journal:  Appl Health Econ Health Policy       Date:  2020-11-02       Impact factor: 2.561

4.  Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model.

Authors:  K Chandra; G Blackhouse; B R McCurdy; M Bornstein; K Campbell; V Costa; J Franek; K Kaulback; L Levin; S Sehatzadeh; N Sikich; M Thabane; R Goeree
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01

5.  Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Authors:  Nadine Hertel; Robert W Kotchie; Yevgeniy Samyshkin; Matthew Radford; Samantha Humphreys; Kevin Jameson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-03-19

6.  Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionals.

Authors:  Sujin Cho; Hochang Kim; Seon-Ha Kim; Minsu Ock; Yeon-Mok Oh; Min-Woo Jo
Journal:  Health Qual Life Outcomes       Date:  2015-03-13       Impact factor: 3.186

Review 7.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

8.  A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.

Authors:  David Price; Yumi Asukai; Jaithri Ananthapavan; Bill Malcolm; Amr Radwan; Ian Keyzor
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

9.  Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Authors:  Yevgeniy Samyshkin; Michael Schlunegger; Susan Haefliger; Sabine Ledderhose; Matthew Radford
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-01-30

10.  Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.

Authors:  Yevgeniy Samyshkin; Robert W Kotchie; Ann-Christin Mörk; Andrew H Briggs; Eric D Bateman
Journal:  Eur J Health Econ       Date:  2013-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.